PAVmed Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de PAVmed de 20.3% y 47.2% respectivamente, mientras que el BPA crecerá en un 65.4% al año.

Información clave

31.8%

Tasa de crecimiento de los beneficios

71.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.7%
Tasa de crecimiento de los ingresos	51.5%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	05 Jun 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

Jul 05

Start Accumulating PAVmed

Dec 24

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

Sep 02

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Aug 23

PAVmed: A True Game-Changer For Medical Device Innovation

Jun 14

PAVmed forms digital health company, Veris Health

Jun 02

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

May 26

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

May 19

PAVmed drops 14% on launch of $13.4M direct offering

Jan 06

PAVmed closes additional direct offering of common stock

Dec 22

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

Dec 16

PAVmed offers stock for $8.9M

Dec 11

PAVmed EPS beats by $0.02

Nov 17

There Is Progress At PAVmed, But More Patience Is Required

Oct 30

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:PAVM - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	101	-15	0	N/A	1
12/31/2025	18	-53	-36	-41	3
12/31/2024	6	-62	-54	-46	3
3/31/2024	3	-71	-49	-49	N/A
12/31/2023	2	-66	-52	-52	N/A
9/30/2023	2	-71	-57	-57	N/A
6/30/2023	1	-79	-69	-65	N/A
3/31/2023	1	-90	-79	-75	N/A
12/31/2022	0	-89	-76	-71	N/A
9/30/2022	1	-86	-79	-71	N/A
6/30/2022	1	-72	-64	-60	N/A
3/31/2022	1	-58	-48	-44	N/A
12/31/2021	1	-51	-44	-41	N/A
9/30/2021	0	-42	-31	-31	N/A
6/30/2021	N/A	-35	-29	-28	N/A
3/31/2021	N/A	-30	-27	-27	N/A
12/31/2020	N/A	-35	-22	-22	N/A
9/30/2020	N/A	-32	-19	-19	N/A
6/30/2020	N/A	-30	-16	-16	N/A
3/31/2020	N/A	-28	-13	-13	N/A
12/31/2019	N/A	-17	-13	-13	N/A
9/30/2019	N/A	-17	-12	-12	N/A
6/30/2019	N/A	-17	-11	-11	N/A
3/31/2019	N/A	-19	-10	-10	N/A
12/31/2018	N/A	-19	-9	-9	N/A
9/30/2018	N/A	-12	-7	-7	N/A
6/30/2018	N/A	-14	-8	-8	N/A
3/31/2018	N/A	-10	-7	-7	N/A
12/31/2017	N/A	-10	N/A	-7	N/A
9/30/2017	N/A	-12	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-5	N/A
3/31/2017	N/A	-9	N/A	-6	N/A
12/31/2016	N/A	-6	N/A	-4	N/A
9/30/2016	N/A	-5	N/A	-4	N/A
6/30/2016	N/A	-3	N/A	-3	N/A
3/31/2016	N/A	-2	N/A	-2	N/A
12/31/2015	N/A	-2	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PAVM siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PAVM siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PAVM siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (47.2% al año) de PAVM crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (47.2% al año) de PAVM crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de PAVM se prevé que sea elevada dentro de 3 años.

PAVmed Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 13%, revenue upgraded

Price target decreased by 21% to US$13.00

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Price target decreased by 48% to US$20.63

Consensus revenue estimates decrease by 12%

Recent updates

Consensus EPS estimates fall by 13%, revenue upgraded

Price target decreased by 21% to US$13.00

Pavmed Inc. Appoints Dennis Matheis to Board of Directors

PAVmed Inc., Annual General Meeting, Jun 20, 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

Price target decreased by 21% to US$16.38

Full year 2023 earnings: EPS exceeds analyst expectations

PAVmed Inc. Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX

PAVmed Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value of the Company’s Listed Securities Under Nasdaq Listing Rule 5550(b)(2)

New major risk - Share price stability

Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?

Now 24% undervalued after recent price drop

Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies

Price target decreased by 48% to US$20.63

Pavmed Inc. Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Pre Cancer Detection

Consensus revenue estimates decrease by 12%

New major risk - Negative shareholders equity

PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Consensus revenue estimates increase by 35%

Consensus revenue estimates decrease by 40%, EPS upgraded

Consensus revenue estimates increase by 33%

No longer forecast to breakeven

PAVmed Receives A Notice from Nasdaq Regarding Minimum Bid Price Requirement

Independent Vice Chairman recently bought US$161k worth of stock

Price target decreased to US$5.06

Consensus forecasts updated

Consensus forecasts updated

Consensus revenue estimates fall by 80%

Price target decreased to US$5.50

Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?

PAVmed Non-GAAP EPS of -$0.17 beats by $0.03

PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress

PAVmed Inc.(NasdaqCM:PAVM) dropped from Russell 2000 Dynamic Index

PAVmed Inc., Annual General Meeting, Jun 21, 2022

PAVmed Inc. announced delayed annual 10-K filing

Consensus revenue estimates fall by 10%

Price target decreased to US$8.13

PAVmed Inc. Appoints Shaun O’Neil as Executive Vice President and Chief Operating Officer

PAVmed Inc. Appoints Joan Harvey to Its Board of Directors

Start Accumulating PAVmed

Consensus forecasts updated

Price target increased to US$9.50

We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Consensus revenue estimates fall to US$1.02m

Independent Director David Battleman has left the company

Independent Director David Weild has left the company

PAVmed: A True Game-Changer For Medical Device Innovation

Consensus forecasts updated

PAVmed forms digital health company, Veris Health

PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics’ EsoCheck and EsoGuard Technologies

PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $41.576088 million.

Price target raised to US$6.42

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device

New 90-day high: US$2.68

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $13.44 million.

PAVmed drops 14% on launch of $13.4M direct offering

New 90-day high: US$2.13

PAVmed Inc. has completed a Follow-on Equity Offering in the amount of $8.1 million.

PAVmed closes additional direct offering of common stock

Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?

PAVmed offers stock for $8.9M

New 90-day high: US$2.06

PAVmed EPS beats by $0.02

New 90-day low: US$1.73

There Is Progress At PAVmed, But More Patience Is Required